CClinicalTrials.gg
Sign In
Not yet recruitingNCT05685329Updated Jun 18, 2023

Determining Patterns In Trial Experiences of Parkinson's Disease Patients

An observational study in Parkinson Disease, sponsored by Power Life Sciences Inc.. Not yet recruiting. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
50 Years to 80 Years
Sex
All
01

Study summary

Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.

This study will invite several participants to gather a wide range of information on clinical trial experiences for Parkinson's Disease patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of Parkinson's Disease.

The data collected from this study will help improve future outcomes for all Parkinson's Disease patients as well as those in under-represented demographic groups.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • Parkinson's
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 500 is above the median of 96 across 1,057 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 108 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with Parkinson's Disease who are actively considering enrolling in an interventional clinical trial for said condition, but have not yet completed enrollment and randomization phases in said clinical trial.

Inclusion criteria

  • Patient plans to participate in an interventional clinical trial for the condition of Parkinson's Disease
  • Patient has been diagnosed with a type of Parkinson's Disease
  • Patient is at least 50 to 80 years of age
  • Patient has access to a home internet connection in order to provide regular updates through the course of the study

Exclusion criteria

Exclusion Criteria:

  • Patient has an ECOG score of 4 or higher
  • Patient is not able to provide consistent digital updates as per study requirements
  • Patient does not complete or agree to terms outlined in the Informed Consent Form
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients who decide to enroll in an Parkinson's Disease clinical trial

    Time frame: 3 months

  2. Rate of patients who remain in Parkinson's Disease clinical trial to trial completion

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Reich SG, Savitt JM. Parkinson's Disease. Med Clin North Am. 2019 Mar;103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3. PubMed 30704685 ↗
  • Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. PubMed 32044947 ↗
  • McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, Stott SRW. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update. J Parkinsons Dis. 2022;12(4):1073-1082. doi: 10.3233/JPD-229002. PubMed 35527571 ↗

Study documents

  • Informed consent form · Jan 5, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05685329
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Feb 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Jun 18, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
(415) 900-4227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Parkinson Disease→

Other studies from this sponsor

Power Life Sciences Inc.

Start the discussion